Legal Representation
Attorney
Meghna Prasad
USPTO Deadlines
Next Deadline
17 days remaining
Non-Final Action E-Mailed - 3-Month Extension Granted (XELG on 2025-10-27)
Due Date
January 25, 2026
Application History
17 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 27, 2025 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Oct 27, 2025 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Jul 25, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 25, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 25, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 23, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 23, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 23, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Mar 18, 2025 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Mar 18, 2025 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Dec 22, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Dec 22, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Dec 22, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 2, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 18, 2024 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Nov 18, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 16, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
a full line of pharmaceuticals for the treatment of depression, malaria, benign prostatic hyperplasia, partial seizures in adults with epilepsy, heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, irritable bowel syndrome (irritable colon, spastic colon, mucous colitis), acute enterocolitis, and duodenal ulcer; anti-inflammatory medicines and immunosuppressive agents (corticosteroids)
First Use Anywhere:
20170300
First Use in Commerce:
20170300
Additional Information
Design Mark
The mark consists of the stylized wording "CONCORDIA", with the prescription symbol "RX" forming the "R" in "CONCORDIA".
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005